Login to Your Account



Analyst: Value 'Inexplicably Low'

Data, Deal, Stroke Therapy: What Can Perk NTI Shares?

By Randall Osborne


Monday, December 10, 2007
Neurobiological Technologies Inc.'s two kernels of news to pop last week - positive interim data from a partner with Xerecept for brain edema, plus a deal with the Buck Institute For Age Research to develop fibroblast growth factor-2 against Huntington's disease - failed to butter up investors, as the value of the firm stayed "inexplicably low," in the words of analyst Russell McAllister of Merriman Curhan Ford. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription